This report is the first to document TEN caused by nivolumab treatment in head and neck cancer. We believe this article can contribute significantly in understanding the principles of nivolumab treatment in patients with head and neck cancer.

No abstract

Nivolumab is used for patients with recurrent/metastatic head and neck cancer resistant to platinum. We report a 76-year-old man with squamous cell carcinoma of the tongue, who developed toxic epidermal necrolysis (TEN) after nivolumab treatment. TEN is a fatal disease, and early treatment of the adverse events are important.

No abstract